IDL Diagnostics AB (publ)

Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.

IDL Diagnostics AB (publ) trades as IDLDX.ST on STO. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in SEK.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

IDL Diagnostics AB (publ) can be compared against peers such as Active Biotech AB (publ), Alligator Bioscience AB (publ), Scandinavian Real Heart AB (Publ), Iconovo AB (publ), Immunovia AB (publ), Luxbright AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $116.10M, beta of 0.86, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IDLDX.ST currently shows total debt of N/A and beta of 0.86. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://idldiagnostics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.